{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:48:53Z","timestamp":1765885733681},"publisher-location":"Berlin, Heidelberg","reference-count":88,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783642042300"},{"type":"electronic","value":"9783642042317"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010]]},"DOI":"10.1007\/978-3-642-04231-7_9","type":"book-chapter","created":{"date-parts":[[2010,11,26]],"date-time":"2010-11-26T10:16:24Z","timestamp":1290766584000},"page":"217-236","source":"Crossref","is-referenced-by-count":14,"title":["Physical Activity and Genitourinary Cancer Survivorship"],"prefix":"10.1007","author":[{"given":"Daniel A.","family":"Galv\u00e3o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis R.","family":"Taaffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Spry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert U.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,8]]},"reference":[{"issue":"6","key":"9_CR1_9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","volume":"56","author":"S Basaria","year":"2002","unstructured":"Basaria S, Lieb J 2nd, Tang AM et al (2002) Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 56(6):779\u2013786","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"9_CR2_9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/cncr.21642","volume":"106","author":"S Basaria","year":"2006","unstructured":"Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS (2006) Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106(3): 581\u2013588","journal-title":"Cancer"},{"issue":"1","key":"9_CR3_9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08870440310001606507","volume":"19","author":"MC Blanchard","year":"2004","unstructured":"Blanchard MC, Stein KD, Baker F et al (2004) Association between current lifestyle behaviors and health-related quality of life in breast, colorectal, and prostate cancer survivors. Psychol Health 19(1):1\u201313","journal-title":"Psychol Health"},{"issue":"6","key":"9_CR4_9","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.urology.2007.09.066","volume":"71","author":"GW Bong","year":"2008","unstructured":"Bong GW, Clarke HS Jr, Hancock WC, Keane TE (2008) Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology 71(6):1177\u20131180","journal-title":"Urology"},{"issue":"24","key":"9_CR5_9","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","volume":"24","author":"M Braga-Basaria","year":"2006","unstructured":"Braga-Basaria M, Dobs AS, Muller DC et al (2006a) Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24(24):3979\u20133983","journal-title":"J Clin Oncol"},{"key":"9_CR6_9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/sj.ijir.3901471","volume":"18","author":"M Braga-Basaria","year":"2006","unstructured":"Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S (2006b) Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 18: 494\u2013498","journal-title":"Int J Impot Res"},{"issue":"10","key":"9_CR7_9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/pon.1023","volume":"15","author":"CL Carmack Taylor","year":"2006","unstructured":"Carmack Taylor CL, Demoor C, Smith MA et al (2006) Active for life after cancer: a randomized trial examining a lifestyle physical activity program for prostate cancer patients. Psychooncology 15(10):847\u2013862","journal-title":"Psychooncology"},{"issue":"5","key":"9_CR8_9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3322\/canjclin.49.5.282","volume":"49","author":"WJ Catalona","year":"1999","unstructured":"Catalona WJ, Ramos CG, Carvalhal GF (1999) Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 49(5):282\u2013296","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"9_CR9_9","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/cncr.10967","volume":"95","author":"Z Chen","year":"2002","unstructured":"Chen Z, Maricic M, Nguyen P et al (2002) Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 95(10):2136\u20132144","journal-title":"Cancer"},{"issue":"11","key":"9_CR10_9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jama.280.11.1008","volume":"280","author":"GW Chodak","year":"1998","unstructured":"Chodak GW (1998) Comparing treatments for localized prostate cancer\u2013persisting uncertainty. JAMA 280(11):1008\u20131010","journal-title":"JAMA"},{"issue":"11","key":"9_CR11_9","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1249\/01.MSS.0000093622.41587.B6","volume":"35","author":"KS Courneya","year":"2003","unstructured":"Courneya KS (2003) Exercise in cancer survivors: an overview of research. Med Sci Sports Exerc 35(11):1846\u20131852","journal-title":"Med Sci Sports Exerc"},{"issue":"1","key":"9_CR12_9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1123\/jsep.29.1.118","volume":"29","author":"SN Culos-Reed","year":"2007","unstructured":"Culos-Reed SN, Robinson JL, Lau H, O\u2019Connor K, Keats MR (2007) Benefits of a physical activity intervention for men with prostate cancer. J Sport Exerc Psychol 29(1):118\u2013127","journal-title":"J Sport Exerc Psychol"},{"issue":"5","key":"9_CR13_9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00520-009-0694-3","volume":"18","author":"SN Culos-Reed","year":"2009","unstructured":"Culos-Reed SN, Robinson JW, Lau H et al (2009) Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention. Support Care Cancer 18(5):591\u2013599","journal-title":"Support Care Cancer"},{"issue":"17","key":"9_CR14_9","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","volume":"25","author":"AV D\u2019Amico","year":"2007","unstructured":"D\u2019Amico AV, Denham JW, Crook J et al (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25(17):2420\u20132425","journal-title":"J Clin Oncol"},{"issue":"5","key":"9_CR15_9","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.urology.2004.11.029","volume":"65","author":"JR Dahn","year":"2005","unstructured":"Dahn JR, Penedo FJ, Molton I et al (2005) Physical activity and sexual functioning after radiotherapy for prostate cancer: beneficial effects for patients undergoing external beam radiotherapy. Urology 65(5):953\u2013958","journal-title":"Urology"},{"issue":"19","key":"9_CR16_9","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1200\/JCO.2007.10.7094","volume":"25","author":"W Demark-Wahnefried","year":"2007","unstructured":"Demark-Wahnefried W, Clipp EC, Lipkus IM et al (2007) Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors. J Clin Oncol 25(19): 2709\u20132718","journal-title":"J Clin Oncol"},{"issue":"1","key":"9_CR17_9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1479-5868-1-16","volume":"1","author":"W Demark-Wahnefried","year":"2004","unstructured":"Demark-Wahnefried W, Clipp EC, Morey MC et al (2004) Physical function and associations with diet and exercise: Results of a cross-sectional survey among elders with breast or prostate cancer. Int J Behav Nutr Phys Act 1(1):16","journal-title":"Int J Behav Nutr Phys Act"},{"issue":"21","key":"9_CR18_9","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1200\/JCO.2006.05.7224","volume":"24","author":"W Demark-Wahnefried","year":"2006","unstructured":"Demark-Wahnefried W, Clipp EC, Morey MC et al (2006) Lifestyle intervention development study to improve physical function in older adults with cancer: outcomes from Project LEAD. J Clin Oncol 24(21):3465\u20133473","journal-title":"J Clin Oncol"},{"issue":"6","key":"9_CR19_9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3322\/canjclin.56.6.323","volume":"56","author":"C Doyle","year":"2006","unstructured":"Doyle C, Kushi LH, Byers T et al (2006) Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 56(6): 323\u2013353","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"9_CR20_9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/cncr.10656","volume":"95","author":"FJ Fowler Jr","year":"2002","unstructured":"Fowler FJ Jr, McNaughton Collins M, Walker Corkery E, Elliott DB, Barry MJ (2002) The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 95(2):287\u2013295","journal-title":"Cancer"},{"issue":"4","key":"9_CR21_9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1200\/JCO.2005.06.085","volume":"23","author":"DA Galv\u00e3o","year":"2005","unstructured":"Galv\u00e3o DA, Newton RU (2005) Review of exercise intervention studies in cancer patients. J Clin Oncol 23(4):899\u2013909","journal-title":"J Clin Oncol"},{"issue":"6","key":"9_CR22_9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/ncpuro1104","volume":"5","author":"DA Galv\u00e3o","year":"2008","unstructured":"Galv\u00e3o DA, Newton RU, Taaffe DR, Spry N (2008a) Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT? Nat Clin Pract Urol 5(6):306\u2013307","journal-title":"Nat Clin Pract Urol"},{"issue":"2","key":"9_CR23_9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/sj.pcan.4500991","volume":"11","author":"DA Galv\u00e3o","year":"2008","unstructured":"Galv\u00e3o DA, Nosaka K, Taaffe DR et al (2008b) Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis 11(2):160\u2013165","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"9_CR24_9","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1249\/01.mss.0000233803.48691.8b","volume":"38","author":"DA Galv\u00e3o","year":"2006","unstructured":"Galv\u00e3o DA, Nosaka K, Taaffe DR et al (2006) Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 38(12):2045\u20132052","journal-title":"Med Sci Sports Exerc"},{"issue":"1","key":"9_CR25_9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/1471-2407-9-419","volume":"9","author":"DA Galv\u00e3o","year":"2009","unstructured":"Galv\u00e3o DA, Spry N, Taaffe DR et al (2009a) A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial. BMC Cancer 9(1):419","journal-title":"BMC Cancer"},{"issue":"1","key":"9_CR26_9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1464-410X.2008.07539.x","volume":"102","author":"DA Galv\u00e3o","year":"2008","unstructured":"Galv\u00e3o DA, Spry NA, Taaffe DR et al (2008c) Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 102(1):44\u201347","journal-title":"BJU Int"},{"issue":"2","key":"9_CR27_9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1200\/JCO.2009.23.2488","volume":"28","author":"DA Galv\u00e3o","year":"2010","unstructured":"Galv\u00e3o DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28(2): 340\u2013347","journal-title":"J Clin Oncol"},{"issue":"2","key":"9_CR28_9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/pcan.2008.51","volume":"12","author":"DA Galv\u00e3o","year":"2009","unstructured":"Galv\u00e3o DA, Taaffe DR, Spry N et al (2009b) Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 12(2):198\u2013203","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"9_CR29_9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/sj.pcan.4500975","volume":"10","author":"DA Galv\u00e3o","year":"2007","unstructured":"Galv\u00e3o DA, Taaffe DR, Spry N, Newton RU (2007) Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer Prostatic Dis 10(4):340\u2013346","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"9_CR30_9","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1210\/jc.2005-0183","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL, Coates P, Sereika SM et al (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90(12):6410\u20136417","journal-title":"J Clin Endocrinol Metab"},{"issue":"9360","key":"9_CR31_9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(03)12713-4","volume":"361","author":"H Gronberg","year":"2003","unstructured":"Gronberg H (2003) Prostate cancer epidemiology. Lancet 361(9360):859\u2013864","journal-title":"Lancet"},{"issue":"2","key":"9_CR32_9","doi-asserted-by":"publisher","first-page":"B95","DOI":"10.1093\/gerona\/55.2.B95","volume":"55","author":"K Hakkinen","year":"2000","unstructured":"Hakkinen K, Pakarinen A, Kraemer WJ, Newton RU, Alen M (2000) Basal concentrations and acute responses of serum hormones and strength development during heavy resistance training in middle-aged and elderly men and women. J Gerontol A Biol Sci Med Sci 55(2):B95\u2013B105","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"9_CR33_9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1046\/j.1464-410X.2002.02529.x","volume":"89","author":"I Hara","year":"2002","unstructured":"Hara I, Miyake H, Hara S et al (2002) Health-related quality of life after radical cystectomy for bladder cancer: a comparison of ileal conduit and orthotopic bladder replacement. BJU Int 89(1): 10\u201313","journal-title":"BJU Int"},{"issue":"4","key":"9_CR34_9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3322\/canjclin.47.4.207","volume":"47","author":"HW Herr","year":"1997","unstructured":"Herr HW (1997) Quality of life in prostate cancer patients. CA Cancer J Clin 47(4):207\u2013217","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"9_CR35_9","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/cncr.21364","volume":"104","author":"JT Hickok","year":"2005","unstructured":"Hickok JT, Roscoe JA, Morrow GR et al (2005) Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer 104(8): 1772\u20131778","journal-title":"Cancer"},{"issue":"5","key":"9_CR36_9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S1078-1439(03)00143-1","volume":"21","author":"CS Higano","year":"2003","unstructured":"Higano CS (2003) Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol 21(5):392\u2013398","journal-title":"Urol Oncol"},{"issue":"34","key":"9_CR37_9","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1200\/JCO.2009.23.6901","volume":"27","author":"MH Hussain","year":"2009","unstructured":"Hussain MH, Wood DP, Bajorin DF et al (2009) Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol 27(34): 5680\u20135684","journal-title":"J Clin Oncol"},{"issue":"2","key":"9_CR38_9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71\u201396","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"9_CR39_9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/sj.pcan.4500800","volume":"8","author":"AV Kaisary","year":"2005","unstructured":"Kaisary AV (2005) Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. Prostate Cancer Prostatic Dis 8(2):140\u2013151","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"9_CR40_9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/pros.20341","volume":"66","author":"H Kaku","year":"2006","unstructured":"Kaku H, Saika T, Tsushima T et al (2006) Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 66(4):439\u2013444","journal-title":"Prostate"},{"issue":"5","key":"9_CR41_9","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/1055-9965.EPI-06-0680","volume":"16","author":"KH Karvinen","year":"2007","unstructured":"Karvinen KH, Courneya KS, North S, Venner P (2007a) Associations between exercise and quality of life in bladder cancer survivors: a population-based study. Cancer Epidemiol Biomark Prev 16(5):984\u2013990","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"2","key":"9_CR42_9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00520-008-0471-8","volume":"17","author":"KH Karvinen","year":"2009","unstructured":"Karvinen KH, Courneya KS, Plotnikoff RC et al (2009) A prospective study of the determinants of exercise in bladder cancer survivors using the Theory of Planned Behavior. Support Care Cancer 17(2):171\u2013179","journal-title":"Support Care Cancer"},{"issue":"1","key":"9_CR43_9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11764-007-0010-5","volume":"1","author":"KH Karvinen","year":"2007","unstructured":"Karvinen KH, Courneya KS, Venner P, North S (2007b) Exercise programming and counseling preferences in bladder cancer survivors: a population-based study. J Cancer Surviv 1(1): 27\u201334","journal-title":"J Cancer Surviv"},{"issue":"1","key":"9_CR44_9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"NL Keating","year":"2009","unstructured":"Keating NL, O\u2019Malley AJ, Freedland SJ, Smith MR (2009) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1):39\u201346","journal-title":"J Natl Cancer Inst"},{"issue":"27","key":"9_CR45_9","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O\u2019Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24(27):4448\u20134456","journal-title":"J Clin Oncol"},{"issue":"3","key":"9_CR46_9","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1152\/jappl.1999.87.3.982","volume":"87","author":"WJ Kraemer","year":"1999","unstructured":"Kraemer WJ, Hakkinen K, Newton RU et al (1999) Effects of heavy-resistance training on hormonal response patterns in younger vs. older men. J Appl Physiol 87(3):982\u2013992","journal-title":"J Appl Physiol"},{"issue":"8","key":"9_CR47_9","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/cncr.21381","volume":"104","author":"H Lee","year":"2005","unstructured":"Lee H, McGovern K, Finkelstein JS, Smith MR (2005) Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 104(8): 1633\u20131637","journal-title":"Cancer"},{"issue":"9056","key":"9_CR48_9","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0140-6736(96)09380-4","volume":"349","author":"GL Lu-Yao","year":"1997","unstructured":"Lu-Yao GL, Yao SL (1997) Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 349(9056): 906\u2013910","journal-title":"Lancet"},{"issue":"1","key":"9_CR49_9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5694\/j.1326-5377.1998.tb141467.x","volume":"169","author":"M McCredie","year":"1998","unstructured":"McCredie M, Cox B (1998) Prostate-specific antigen testing for prostate cancer: the case for informed consent. Med J Aust 169(1):9\u201310","journal-title":"Med J Aust"},{"issue":"4","key":"9_CR50_9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3322\/CA.2008.0002","volume":"58","author":"MD Michaelson","year":"2008","unstructured":"Michaelson MD, Cotter SE, Gargollo PC et al (2008) Management of complications of prostate cancer treatment. CA Cancer J Clin 58(4): 196\u2013213","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"9_CR51_9","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1200\/JCO.2005.07.116","volume":"23","author":"DC Miller","year":"2005","unstructured":"Miller DC, Sanda MG, Dunn RL et al (2005) Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 23(12): 2772\u20132780","journal-title":"J Clin Oncol"},{"issue":"11","key":"9_CR52_9","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.apmr.2007.08.110","volume":"88","author":"U Monga","year":"2007","unstructured":"Monga U, Garber SL, Thornby J et al (2007) Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. Arch Phys Med Rehabil 88(11): 1416\u20131422","journal-title":"Arch Phys Med Rehabil"},{"issue":"18","key":"9_CR53_9","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1001\/jama.2009.643","volume":"301","author":"MC Morey","year":"2009","unstructured":"Morey MC, Snyder DC, Sloane R et al (2009) Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. Jama 301(18):1883\u20131891","journal-title":"Jama"},{"issue":"6","key":"9_CR54_9","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/S0022-5347(05)67511-8","volume":"163","author":"JW Moul","year":"2000","unstructured":"Moul JW (2000) Prostate specific antigen only progression of prostate cancer. J Urol 163(6): 1632\u20131642","journal-title":"J Urol"},{"key":"9_CR55_9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/1471-2407-9-210","volume":"9","author":"RU Newton","year":"2009","unstructured":"Newton RU, Taaffe DR, Spry N et al (2009) A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer. BMC Cancer 9:210","journal-title":"BMC Cancer"},{"issue":"15","key":"9_CR56_9","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1200\/JCO.2005.12.187","volume":"23","author":"S Oudard","year":"2005","unstructured":"Oudard S, Banu E, Beuzeboc P et al (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refrac-tory prostate cancer. J Clin Oncol 23(15): 3343\u20133351","journal-title":"J Clin Oncol"},{"issue":"1","key":"9_CR57_9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1152\/japplphysiol.00294.2004","volume":"98","author":"JK Petrella","year":"2005","unstructured":"Petrella JK, Kim JS, Tuggle SC, Hall SR, Bamman MM (2005) Age differences in knee extension power, contractile velocity, and fatigability. J Appl Physiol 98(1):211\u2013220","journal-title":"J Appl Physiol"},{"issue":"15","key":"9_CR58_9","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513\u20131520","journal-title":"N Engl J Med"},{"issue":"8","key":"9_CR59_9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0002-9343(02)01235-4","volume":"113","author":"DF Ransohoff","year":"2002","unstructured":"Ransohoff DF, McNaughton Collins M, Fowler FJ (2002) Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med 113(8):663\u2013667","journal-title":"Am J Med"},{"issue":"3","key":"9_CR60_9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1634\/theoncologist.9-3-295","volume":"9","author":"MH Rashid","year":"2004","unstructured":"Rashid MH, Chaudhary UB (2004) Intermittent androgen deprivation therapy for prostate cancer. Oncologist 9(3):295\u2013301","journal-title":"Oncologist"},{"issue":"7","key":"9_CR61_9","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/cncr.22933","volume":"110","author":"CS Saigal","year":"2007","unstructured":"Saigal CS, Gore JL, Krupski TL et al (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110(7):1493\u2013500","journal-title":"Cancer"},{"issue":"7","key":"9_CR62_9","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1158\/1055-9965.EPI-04-0703","volume":"14","author":"KH Schmitz","year":"2005","unstructured":"Schmitz KH, Holtzman J, Courneya KS et al (2005) Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 14(7): 1588\u20131595","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"9","key":"9_CR63_9","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1200\/JCO.2003.09.534","volume":"21","author":"RJ Segal","year":"2003","unstructured":"Segal RJ, Reid RD, Courneya KS et al (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21(9):1653\u20131659","journal-title":"J Clin Oncol"},{"issue":"3","key":"9_CR64_9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2007.15.4963","volume":"27","author":"RJ Segal","year":"2009","unstructured":"Segal RJ, Reid RD, Courneya KS et al (2009) Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 27(3): 344\u2013351","journal-title":"J Clin Oncol"},{"issue":"2","key":"9_CR65_9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005a) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2): 154\u2013164","journal-title":"N Engl J Med"},{"issue":"4","key":"9_CR66_9","first-page":"465","volume":"166","author":"VB Shahinian","year":"2006","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2006) Risk of the \u201candrogen deprivation syndrome\u201d in men receiving androgen deprivation for prostate cancer. Arch Intern Med 166(4): 465\u2013471","journal-title":"Arch Intern Med"},{"issue":"8","key":"9_CR67_9","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/cncr.20955","volume":"103","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS (2005b) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103(8):1615\u20131624","journal-title":"Cancer"},{"issue":"2","key":"9_CR68_9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. Jama 294(2):238\u2013244","journal-title":"Jama"},{"issue":"9","key":"9_CR69_9","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1210\/jc.86.9.4261","volume":"86","author":"JC Smith","year":"2001","unstructured":"Smith JC, Bennett S, Evans LM et al (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86(9):4261\u20134267","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9_CR70_9","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.urology.2003.10.063","volume":"63","author":"MR Smith","year":"2004","unstructured":"Smith MR (2004) Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 63(4):742\u2013745","journal-title":"Urology"},{"issue":"2","key":"9_CR71_9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/jc.87.2.599","volume":"87","author":"MR Smith","year":"2002","unstructured":"Smith MR, Finkelstein JS, McGovern FJ et al (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87(2):599\u2013603","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"9_CR72_9","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/cncr.23440","volume":"112","author":"MR Smith","year":"2008","unstructured":"Smith MR, Lee H, McGovern F et al (2008) Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 112(10):2188\u20132194","journal-title":"Cancer"},{"issue":"4","key":"9_CR73_9","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1210\/jc.2005-2507","volume":"91","author":"MR Smith","year":"2006","unstructured":"Smith MR, Lee H, Nathan DM (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91(4): 1305\u20131308","journal-title":"J Clin Endocrinol Metab"},{"issue":"31","key":"9_CR74_9","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Lee WC, Brandman J et al (2005) Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23(31):7897\u20137903","journal-title":"J Clin Oncol"},{"issue":"6","key":"9_CR75_9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1464-410X.2009.08458.x","volume":"104","author":"NA Spry","year":"2009","unstructured":"Spry NA, Galv\u00e3o DA, Davies R et al (2009) Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU Int 104(6):806\u2013812","journal-title":"BJU Int"},{"issue":"8","key":"9_CR76_9","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.ejca.2006.01.029","volume":"42","author":"NA Spry","year":"2006","unstructured":"Spry NA, Kristjanson L, Hooton B et al (2006) Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 42(8):1083\u20131092","journal-title":"Eur J Cancer"},{"issue":"3","key":"9_CR77_9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/jama.283.3.354","volume":"283","author":"JL Stanford","year":"2000","unstructured":"Stanford JL, Feng Z, Hamilton AS et al (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. Jama 283(3):354\u2013360","journal-title":"Jama"},{"issue":"22","key":"9_CR78_9","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/NEJMoa031918","volume":"350","author":"IM Thompson","year":"2004","unstructured":"Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350(22):2239\u20132246","journal-title":"N Engl J Med"},{"issue":"20","key":"9_CR79_9","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1093\/jnci\/djm168","volume":"99","author":"HK Tsai","year":"2007","unstructured":"Tsai HK, D\u2019Amico AV, Sadetsky N, Chen MH, Carroll PR (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99(20): 1516\u20131524","journal-title":"J Natl Cancer Inst"},{"issue":"9198","key":"9_CR80_9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0140-6736(99)03473-X","volume":"355","author":"M Kampen Van","year":"2000","unstructured":"Van Kampen M, De Weerdt W, Van Poppel H et al (2000) Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial. Lancet 355(9198):98\u2013102","journal-title":"Lancet"},{"issue":"2","key":"9_CR81_9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.critrevonc.2008.06.006","volume":"68","author":"GJ Londen van","year":"2008","unstructured":"van Londen GJ, Levy ME, Perera S, Nelson JB, Greenspan SL (2008) Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. Crit Rev Oncol Hematol 68(2):172\u2013177","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9141","key":"9_CR82_9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(98)01041-1","volume":"352","author":"NJ Vogelzang","year":"1998","unstructured":"Vogelzang NJ, Stadler WM (1998) Kidney cancer. Lancet 352(9141):1691\u20131696","journal-title":"Lancet"},{"issue":"17","key":"9_CR83_9","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H Maase von der","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17):3068\u20133077","journal-title":"J Clin Oncol"},{"issue":"3","key":"9_CR84_9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/cncr.20378","volume":"101","author":"PM Windsor","year":"2004","unstructured":"Windsor PM, Nicol KF, Potter J (2004) A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer 101(3):550\u2013557","journal-title":"Cancer"},{"issue":"5","key":"9_CR85_9","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1200\/JCO.2008.21.2134","volume":"27","author":"E Winer","year":"2009","unstructured":"Winer E, Gralow J, Diller L et al (2009) Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening\u2013a report from the American Society of Clinical Oncology. J Clin Oncol 27(5):812\u2013826","journal-title":"J Clin Oncol"},{"issue":"2","key":"9_CR86_9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.juro.2009.09.082","volume":"183","author":"KY Wolin","year":"2010","unstructured":"Wolin KY, Luly J, Sutcliffe S, Andriole GL, Kibel AS (2010) Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity. J Urol 183(2):629\u2013633","journal-title":"J Urol"},{"issue":"5","key":"9_CR87_9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1122::AID-CNCR24>3.0.CO;2-Q","volume":"88","author":"Y Yan","year":"2000","unstructured":"Yan Y, Carvalhal GF, Catalona WJ, Young JD (2000) Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 88(5):1122\u20131130","journal-title":"Cancer"},{"issue":"4","key":"9_CR88_9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.2001.19.4.1147","volume":"19","author":"R Yancik","year":"2001","unstructured":"Yancik R, Ganz PA, Varricchio CG, Conley B (2001) Perspectives on comorbidity and cancer in older patients: approaches to exp-and the knowledge base. J Clin Oncol 19(4): 1147\u20131151","journal-title":"J Clin Oncol"}],"container-title":["Recent Results in Cancer Research","Physical Activity and Cancer"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-04231-7_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T07:27:31Z","timestamp":1557818851000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-04231-7_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"ISBN":["9783642042300","9783642042317"],"references-count":88,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-04231-7_9","relation":{},"ISSN":["0080-0015"],"issn-type":[{"type":"print","value":"0080-0015"}],"subject":[],"published":{"date-parts":[[2010]]}}}